215 related articles for article (PubMed ID: 17240107)
1. Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin.
Ednie L; Shapiro S; Appelbaum PC
Diagn Microbiol Infect Dis; 2007 May; 58(1):133-6. PubMed ID: 17240107
[TBL] [Abstract][Full Text] [Related]
2. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
3. ["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].
Litterio M; Bianchini H; Carloni G; Di Martino A; Fernández Canigia L; Greco G; Legaria C; Rollet R; Rossetti A; Predari SC; Castello L
Rev Argent Microbiol; 2004; 36(3):130-5. PubMed ID: 15559195
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
Pillar CM; Aranza MK; Shah D; Sahm DF
J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the in vitro activity of ertapenem and nine other comparator agents against 337 anaerobic bacteria.
Behra-Miellet J; Dubreuil L; Calvet L
Int J Antimicrob Agents; 2006 Jul; 28(1):25-35. PubMed ID: 16757152
[TBL] [Abstract][Full Text] [Related]
6. [Role of obligate anaerobes in infections in hospitalized patients and therapeutic options].
Wróblewska M; Rokosz A; Sawicka-Grzelak A; Kot K; Luczak M
Med Dosw Mikrobiol; 2005; 57(2):199-208. PubMed ID: 16134392
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.
Walkty A; Adam HJ; Laverdière M; Karlowsky JA; Hoban DJ; Zhanel GG;
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):348-55. PubMed ID: 21353964
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
Citron DM; Appleman MD
Antimicrob Agents Chemother; 2001 Jan; 45(1):345-8. PubMed ID: 11120995
[TBL] [Abstract][Full Text] [Related]
10. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.
Credito KL; Appelbaum PC
Antimicrob Agents Chemother; 2004 Nov; 48(11):4430-4. PubMed ID: 15504874
[TBL] [Abstract][Full Text] [Related]
11. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study.
Rossolini GM; Dryden MS; Kozlov RS; Quintana A; Flamm RK; Läuffer JM; Lee E; Morrissey I; CLASS Study Group
J Antimicrob Chemother; 2011 Jan; 66(1):151-9. PubMed ID: 21051375
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
13. [In vitro activity of 10 antibiotics including pristinamycin and its two components (RP 12536 and 27404) against strict anaerobes].
Dubreuil L; Houcke I; Singer E
Pathol Biol (Paris); 1998 Feb; 46(2):147-52. PubMed ID: 9769928
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
Snydman DR; Jacobus NV; McDermott LA
Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
[TBL] [Abstract][Full Text] [Related]
15. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.
Putnam SD; Castanheira M; Moet GJ; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):393-401. PubMed ID: 20022192
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
17. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
[TBL] [Abstract][Full Text] [Related]
18. [Susceptibility of strict anaerobic bacteria to antibiotics in France: a multicenter study].
Grollier G; Mory F; Quentin C; Girard-Pipau F; Tigaud S; Sedallian A; Dubreuil L
Pathol Biol (Paris); 1994 May; 42(5):498-504. PubMed ID: 7824321
[TBL] [Abstract][Full Text] [Related]
19. [Antibiotic sensitivity of anaerobic bacteria isolated during one year (1993)].
Durán MT; Molina F
Enferm Infecc Microbiol Clin; 1996; 14(6):370-6. PubMed ID: 8756216
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
Appelbaum PC; Spangler SK; Jacobs MR
J Antimicrob Chemother; 1993 Aug; 32(2):223-31. PubMed ID: 8226424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
